Orthobiologics in Equine Musculoskeletal Injuries

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Equids".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 2567

Special Issue Editors


E-Mail Website
Guest Editor
Laboratorio de Genética Bioquímica (LAGENBIO), Instituto Agroalimentario de Aragón IA2 - Instituto de Investigación Sanitaria de Aragón IIS, Universidad de Zaragoza, 50013, Zaragoza, Spain
Interests: equine articular cartilage repair; equine osteoarthritis model; mesenchymal stem cells; orthobiologics; immunology; translational research

E-Mail Website
Guest Editor
Laboratorio de Genética Bioquímica (LAGENBIO), Instituto Agroalimentario de Aragón IA2 - Instituto de Investigación Sanitaria de Aragón - IIS, Universidad de Zaragoza, 50013 Zaragoza, Spain
Interests: osteoarthritis; mesenchymal stem cells; orthobiologics; equine model; translational research; animal genetics

Special Issue Information

Dear Colleagues,

Musculoskeletal injuries are among the most common pathologic conditions in the equine species, mainly owing to the highly demanding sportive activities in which horses participate. The limited healing capacity of tendons, ligaments, or cartilage constitutes a handicap in the management of these injuries, resulting in a repaired tissue of inferior biomechanical properties. Advanced therapies involving the use of different orthobiologics, such as stem cells or acellular products, are showing encouraging results to treat these injuries, and a growing number of products are being developed and commercialized. In this rapidly evolving field, it is critical to keep up-to-date with the most recent evidence-based knowledge. This Special Issue will collect articles on the use of orthobiologics to advance the treatment of musculoskeletal injuries in horse, including literature reviews and research articles, from experimental in vitro and in vivo studies to trials and case reports. The overarching goal of this Special Issue is to serve as a useful collection of up-to-date high-quality information to contribute to the advancement of the field, owing to the relevance of the horse as a patient and as a translational large animal model.

Dr. Laura Barrachina
Prof. Clementina Rodellar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Orthobiologics
  • Stem cells
  • Acellular products
  • Tendon and ligament injuries
  • Cartilage defects
  • Osteoarthritis
  • Translational medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 2206 KiB  
Article
Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility
by Alina Cequier, Antonio Romero, Francisco J. Vázquez, Arantza Vitoria, Elvira Bernad, Sara Fuente, Pilar Zaragoza, Clementina Rodellar and Laura Barrachina
Animals 2022, 12(8), 984; https://doi.org/10.3390/ani12080984 - 11 Apr 2022
Cited by 4 | Viewed by 1829
Abstract
Immunomodulation and immunogenicity are pivotal aspects for the therapeutic use of mesenchymal stem cells (MSCs). Since the horse is highly valuable as both a patient and translational model, further knowledge on equine MSC immune properties is required. This study analysed how inflammation, chondrogenic [...] Read more.
Immunomodulation and immunogenicity are pivotal aspects for the therapeutic use of mesenchymal stem cells (MSCs). Since the horse is highly valuable as both a patient and translational model, further knowledge on equine MSC immune properties is required. This study analysed how inflammation, chondrogenic differentiation and compatibility for the major histocompatibility complex (MHC) influence the MSC immunomodulatory–immunogenicity balance. Equine MSCs in basal conditions, pro-inflammatory primed (MSC-primed) or chondrogenically differentiated (MSC-chondro) were co-cultured with either autologous or allogeneic MHC-matched/mismatched lymphocytes in immune-suppressive assays (immunomodulation) and in modified one-way mixed leukocyte reactions (immunogenicity). After co-culture, frequency and proliferation of T cell subsets and B cells were assessed by flow cytometry and interferon-ɣ (IFNɣ) secretion by ELISA. MSC-primed showed higher regulatory potential by decreasing proliferation of cytotoxic and helper T cells and B cells. However, MHC-mismatched MSC-primed can also activate lymphocytes (proliferative response and IFNɣ secretion), likely due to increased MHC-expression. MSC-chondro maintained their regulatory ability and did not increase their immunogenicity, but showed less capacity than MSC-primed to induce regulatory T cells and further stimulated B cells. Subsequent in vivo studies are needed to elucidate the complex interactions between MSCs and the recipient immune system, which is critical to develop safe and effective therapies. Full article
(This article belongs to the Special Issue Orthobiologics in Equine Musculoskeletal Injuries)
Show Figures

Figure 1

Back to TopTop